Ulipristal Acetate
- Chemical Name:Ulipristal Acetate
- CAS No.:126784-99-4
- MF:C30H37NO4
- MW:475.62
- Purity:≥98% or according to customer requested
- Color: white to beige
- Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;API;Hormones and the Endocrine System
- Test method: HPLC
Description
What is Ulipristal Acetate?
Ulipristal Acetate is an orally bioavailable, acetate salt of ulipristal, a selective progesterone receptor modulator with anti-progesterone activity. Ulipristal binds to the progesterone receptor (PR), thereby inhibiting PR-mediated gene expression, and interfering with progesterone activity in the reproductive system. As a result, this agent may suppress the growth of uterine leiomyomatosis. Furthermore, by inhibiting or delaying ovulation and effecting endometrial tissue, ulipristal can be used as an emergency contraception. (Source: NCI Thesaurus (NCIt))
Product Name: | Ulipristal Acetate |
Synonyms: | Ulipristal; Ulipristal acetate; EllaOne; Ulipristal acet; Ulipristal acetate 98%; CDB 2914 |
CAS: | 126784-99-4 |
MF: | C30H37NO4 |
MW: | 475.62 |
EINECS: | 682-170-1 |
Product Categories: | Intermediates & Fine Chemicals; Pharmaceuticals; API; Hormones and the Endocrine System |
Melting point | 183-185 ºC |
Boiling point | 640.1±55.0 °C(Predicted) |
density | 1.19 |
storage temp. | -20°C |
pka | 5.49±0.24(Predicted) |
form | powder |
color | white to beige |
optical activity | [α]/D +165 to +185°, c = 1 in dichloromethane |
Ulipristal acetate, a selective progesterone receptor modulator (SPRM), was developed at the Research Triangle Institute. In 2009, HRA Pharma received FDA approval for emergency contraception within 120 h (5 days) of unprotected sexual intercourse or contraceptive failure. Ulipristal acetate is a well-known steroid that possesses antiprogestational and antiglucocorticoid activity. It is the first SPRM that was specifically designed as an oral emergency contraceptive. Unlike earlier levonorgestrel-based emergency contraceptives, this SPRM drug maintains efficacy for 5 days after unprotected intercourse while having safety profile comparable to levonorgestrel.
Technical Support & Resources
Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
MSDS: MSDS available.
COA: COA can be available if you send us inquiry.
Email us at: info@maxmedchem.com for more details.